ProMIS Neurosciences (PMN), a biotech focused on Alzheimer’s disease therapeutics, highlighted encouraging interim results from its Phase 1b PRECISE-AD trial at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company’s PMN310 candidate demonstrated a robust safety profile, with zero treatment-related serious adverse events or discontinuations among 128 patients over a 6-month blinded analysis. Safety metrics aligned closely with untreated Alzheimer’s patients, including a 4.4% incidence of ARIA-H (hemorrhagic microbleeds), far below the 20%-30% range seen in approved anti-amyloid therapies like lecanemab and donanemab.
ProMIS Neurosciences Reports Phase 1b Alzheimer’s Trial Safety Data at Cantor Conference
The biotech firm’s PMN310 drug shows promising safety profile in early-stage study, with no serious adverse events and minimal ARIA risks compared to competitors.
SL
Sophie Laurent · FX & Rates Desk · 17 Sept 2026 · 02:32 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
SL
Written by
Sophie Laurent
FX & Rates Desk
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
